Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection

Article Properties
Cite
Kaya, Mahmut, et al. “Non-Infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection”. Turkish Journal of Ophthalmology, vol. 51, no. 1, 2021, pp. 32-37, https://doi.org/10.4274/tjo.galenos.2020.84042.
Kaya, M., Öner, F. H., Akbulut Yağcı, B., Ataş, F., & Öztürk, T. (2021). Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection. Turkish Journal of Ophthalmology, 51(1), 32-37. https://doi.org/10.4274/tjo.galenos.2020.84042
Kaya M, Öner FH, Akbulut Yağcı B, Ataş F, Öztürk T. Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection. Turkish Journal of Ophthalmology. 2021;51(1):32-7.
Journal Category
Medicine
Ophthalmology
Citations
Title Journal Journal Categories Citations Publication Date
Vitreous Opacity Following Intravitreal Brolucizumab Injection: A Case Series Review

 Korean Journal of Ophthalmology
  • Medicine: Ophthalmology
 2024
Scutellarein ameliorates inflammation and oxidative stress in L-arginine induced acute pancreatitis in mice through regulating the expression of VEGF Molecular & Cellular Toxicology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Science: Biology (General)
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 2023
Retinal vasculitis as the presenting sign of post-injection endophthalmitis Journal Français d'Ophtalmologie
  • Medicine: Medicine (General)
  • Medicine: Ophthalmology
 2023
Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration

 Scientific Reports
  • Medicine
  • Science
  • Science: Science (General)
 2023
Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study

 Ophthalmologica
  • Medicine: Medicine (General)
  • Medicine: Ophthalmology
 2 2023
Citations Analysis
Category Category Repetition
Medicine: Ophthalmology5
Medicine: Medicine (General)3
Medicine1
Science1
Science: Science (General)1
Medicine: Public aspects of medicine: Toxicology. Poisons1
Science: Biology (General)1
The category Medicine: Ophthalmology 5 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Aflibercept/ranibizumab and was published in 2021. The most recent citation comes from a 2024 study titled Vitreous Opacity Following Intravitreal Brolucizumab Injection: A Case Series Review. This article reached its peak citation in 2023, with 4 citations. It has been cited in 9 different journals, 33% of which are open access. Among related journals, the Ophthalmologica cited this research the most, with 2 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year